非何傑金氏淋巴癌病徵, 成因及治療
> 非何傑金氏淋巴癌
非何傑金氏淋巴癌
非何傑金氏癌是淋巴系統的癌病
淋巴癌主要有兩大類：非何傑金氏癌和何傑金氏癌
淋巴細胞通常在淋巴系統內的淋巴結內擴散，但有時這些癌細胞也可能進入血液，到不同的器官
當這些癌細胞抵達一個新地方後，他們會繼續分裂，形成一個新腫瘤
即使非何傑金氏淋巴癌擴散到其他的器官，多年來治療的方法已有相當的改善，越來越多的人得以治癒
淋巴系統是免疫系統的一部分, 可以保護身體的組織，抵抗疾病和感染
淋巴系統是由細管組成的網絡，像河流系統一般貫穿全身。淋巴管運送的清澈液體就是淋巴液
甚麼引致非何傑金氏淋巴癌
大多數非何傑金氏淋巴癌的起因不得而知，但這方面的研究一直在進行
研究人員正在調查各種情況，例如器官移植後採用防止排斥的藥物等，會不會增加患上淋巴癌的機會
如其他癌病，非何傑金氏淋巴癌沒有傳染性，不會傳染給別人
非何傑金氏淋巴癌的症狀？
非何傑金氏淋巴癌最初的症狀通常是在頸內、腋窩或腹股溝內有一團不痛的腫塊
大量流汗或發燒，尤其是在夜晚
全身持續痕癢
食慾不振、體重下降和感到疲累
兒童或許會患上咳嗽或喘氣，也可能埋怨腹痛，或許你會察覺孩子的腹內有一硬塊
假如你或你的孩子有以上任何的症狀，必須請醫生檢查。但記著，除了何傑金氏淋巴癌以外，許多疾病都有相同的症狀，而大多數有這些症狀的人，並不是患上了非何傑金氏淋巴癌。
非何傑金氏癌在香港普遍嗎？
請瀏覽最新癌症統計資料何杰金氏淋巴瘤有哪些症状表现
温馨提示： 淋巴癌在我国的发病率很高，死亡率也很高。淋巴癌用不同的种类，何杰金氏淋巴瘤就是其中的一种。接下来笔者就介绍下什么是何杰金氏淋巴瘤?何杰金氏淋巴瘤有哪些症状表现?
阅读了本篇文章的用户还阅读了
根据阅读为你提供的用药资讯
胃炎是由多种原因引起的胃粘膜慢性炎症性疾病，对慢性胃炎治疗应及早...
瑞婷(阿那曲唑片)抑制雌激素合成，能有效治疗激素敏感性乳腺癌病人......非何杰金淋巴瘤非何杰金氏淋巴瘤的開發中產品分析
Non-Hodgkin Lymphoma - Pipeline Review, H2 2015
出版日期: 日
內容資訊: 英文 969 Pages
非何杰金氏淋巴瘤(NHL，或僅稱「淋巴瘤」)，是從人體免疫系統淋巴球發病的癌症的一種。會從人體處開始出現，進展又會多麼快速完全因人而異。主要的症狀有盜汗、間歇性發熱·發冷、發癢、頭部·腋下·鼠蹊部等淋巴節肥大化、體重減少、咳嗽·呼吸急促(胸腺和胸部淋巴節受侵襲)、氣管和其他呼吸道的壓迫感、腹痛·膨脹感、食慾不振、便秘、噁心·嘔吐·頭痛、集中力的欠缺、人格變化、癲癇(腦受侵襲)等。主要的治療方法有外科手術和放射治療、化療等。
本報告提供全球各國治療非何杰金氏淋巴瘤用的開發中產品之開發情形相關分析，提供您產品開發·上市的最新趨勢，及臨床實驗各階段的產品一覽，再加上主要企業簡介，主要藥物概要，最新的產業趨勢等資訊。
非何杰金氏淋巴瘤概要
治療藥的開發
非何杰金氏淋巴瘤開發中產品:概要
非何杰金氏淋巴瘤開發中產品:比較分析
各企業開發中的非何杰金氏淋巴瘤治療藥
大學/研究機關研究中的非何杰金氏淋巴瘤治療藥
開發中產品的概要
後期階段的產品
臨床實驗階段的產品
初期階段的產品
不明確的階段的產品
非何杰金氏淋巴瘤治療藥:開發中的產品一覽(各企業)
非何杰金氏淋巴瘤治療藥:研究中的產品的一覽(大學/研究機關別)
非何杰金氏淋巴瘤治療藥的開發企業
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Amgen Inc.
Eli Lilly and Company
Seattle Genetics, Inc.
Genentech, Inc.
Gilead Sciences, Inc.
Merck & Co., Inc.
Gamida Cell Ltd.
BioLineRx, Ltd.
Celltrion, Inc.
ZIOPHARM Oncology, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
Richter Gedeon Nyrt.
ImmunoGen, Inc.
Pfizer Inc.
Sigma-Tau S.p.A.
Astex Pharmaceuticals, Inc.
Cell Therapeutics, Inc.
Celgene Corporation
Immunomedics, Inc.
Idera Pharmaceuticals, Inc.
TG Therapeutics, Inc.
Curis, Inc.
Accentia Biopharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
Mundipharma International Limited
Pharmacyclics, Inc.
Dynavax Technologies Corporation
MorphoSys AG
BioInvent International AB
Xenetic Biosciences plc.
TaKaRa BIO
Panacea Biotec Limited
Transgene Biotek Limited
Spectrum Pharmaceuticals, Inc.
Affimed Therapeutics AG
CIMAB S.A.
Supratek Pharma Inc.
Memgen, LLC
Actinium Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
ProNAi Therapeutics, Inc.
Grupo Ferrer Internacional, S.A.
Onconova Therapeutics, Inc.
Kainos Medicine, Inc.
Acetylon Pharmaceuticals, Inc.
Taiwan Liposome Company, Ltd.
Xcovery, Inc.
Pharma Mar, S.A.
Bellicum Pharmaceuticals, Inc.
Biothera, Inc.
Sigma-Tau Pharmaceuticals, Inc.
EpiZyme, Inc.
NuCana BioMed Limited
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Biosidus S.A.
Polaris Group
Fountain Biopharma Inc.
Karyopharm Therapeutics, Inc.
Inbiopro Solutions Pvt. Ltd.
Conkwest, Inc.
International Biotechnology Center Generium
Oncobiologics, Inc.
Mission Therapeutics Ltd.
bioXPRESS Therapeutics SA
Avipep Pty Ltd
Nordic Nanovector AS
Tolero Pharmaceuticals, Inc.
Innovent Biologics, Inc.
AbbVie Inc.
AlphaMab Co., Ltd.
ash陽台·amujen·生物製藥
非何杰金氏淋巴瘤:治療藥的評估
單劑治療藥的情況
各作用機制
各分子類型
dasiprotimut T
研究開發(R&D)的發展情形
procarbazine hydrochloride
pixantrone dimaleate
obinutuzumab
vincristine sulfate liposomal
lenalidomide
PGG beta-glucan
rituximab biosimilar
veltuzumab
bendamustine
alvocidib hydrocholride
blinatumomab
brentuximab vedotin
mocetinostat
agatolimod sodium
forodesine hydrochloride
plitidepsin
copanlisib
atorvastatin calcium
epratuzumab
pegargiminase
Allogeneic Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes
abexinostat hydrochloride
CD19CAR/Virus Specific T Cells
Minor Histocompatibility Antigen
Chimeric Anti-CD20 Monoclonal Antibody
pictilisib
vinorelbine tartrate liposomal
SAR-650984
darinaparsin
briciclib sodium
EBV-Specific T-Lymphocytes
LY-2780301
Autologous CAR.CD30 EBV Specific Cytotoxic T Lymphocytes
LMP Specific Cytotoxic T-Lymphocytes
rituximab biosimilar
HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes
pembrolizumab
venetoclax
vincristine sulfate liposomal
Genetically Modified T Cell
TG-1101 + TGR-1202
LMP-Specific Cytotoxic T Cells
rituximab biosimilar
bendamustine hydrochloride
ricolinostat
rituximab biosimilar
CD19-CAR Gene Therapy
tenatumomab
TBL-0306-L
rituximab biosimilar
Oncology Program
vinorelbine
rituximab biosimilar
Ritonavir Analogs
rituximab biosimilar
rituximab biosimilar
EPZ-005687
rituximab biosimilar
Small Molecule for Hematologic Malignancies
IBPM-001-RX
rituximab biosimilar
rituximab biosmiliar
rituximab biosimilar
rituximab biosimilar
非何杰金氏淋巴瘤治療藥:開發中產品的最新趨勢
非何杰金氏淋巴瘤治療藥:開發暫停的產品
非何杰金氏淋巴瘤治療藥:開發中止的產品
非何杰金氏淋巴瘤相關產品的開發里程碑
值得注意的最新趨勢·新聞稿(全10件)
Global Markets Direct's, 'Non-Hodgkin Lymphoma - Pipeline Review, H2 2015', provides an overview of the Non-Hodgkin Lymphoma's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Non-Hodgkin Lymphoma and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
Introduction
Non-Hodgkin Lymphoma Overview
Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics under Development by Companies
Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes
Non-Hodgkin Lymphoma - Pipeline Products Glance
Non-Hodgkin Lymphoma - Products under Development by Companies
Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics Assessment
Drug Profiles
Non-Hodgkin Lymphoma - Recent Pipeline Updates
Non-Hodgkin Lymphoma - Dormant Projects
Non-Hodgkin Lymphoma - Discontinued Products
Non-Hodgkin Lymphoma - Product Development Milestones
List of Tables
Number of Products under Development for Non-Hodgkin Lymphoma, H2 2015
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2015
Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Actelion Ltd, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Agilvax, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Allinky Biopharma, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Arbutus Biopharma Corporation, H2 2015
Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Atara Biotherapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by BioAtla, LLC, H2 2015
Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H2 2015
Non-Hodgkin Lymphoma - Pipeline by BioLineRx, Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Bionovis SA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by BioSight Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Biothera, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Boston Biomedical, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Calimmune, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Celon Pharma Sp. z o.o., H2 2015
Non-Hodgkin Lymphoma - Pipeline by CerRx, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Chipscreen Biosciences Ltd, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Formula Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Galderma S.A., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Hospira, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by iDD biotech SAS, H2 2015
Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H2 2015
Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Innate Pharma SA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Inventiva SAS, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Kainos Medicine, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Kite Pharma, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Komipharm International Co., Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by miRagen Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Mirna Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Mundipharma International Ltd, H2 2015
Non-Hodgkin Lymphoma - Pipeline by NantKwest, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2015
Non-Hodgkin Lymphoma - Pipeline by OncoSec Medical Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Onxeo SA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Oxford BioTherapeutics Ltd, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Panacea Biotec Limited, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Pharma Mar, S.A., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Polaris Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by
Rhizen Pharmaceuticals S.A., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Richter Gedeon Nyrt., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Sanofi, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Sareum Holdings Plc, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Senhwa Biosciences, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Solasia Pharma K.K., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Soligenix, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Supratek Pharma Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Targazyme, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by TetraLogic Pharmaceuticals, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Transgene Biotek Limited, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Vivia Biotech, S.L., H2 2015
Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences plc, H2 2015
Non-Hodgkin Lymphoma - Pipeline by Zymeworks Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Non-Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015
Non-Hodgkin Lymphoma - Dormant Projects, H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H2 2015
Non-Hodgkin Lymphoma - Dormant Projects (Contd..13), H2 2015
Non-Hodgkin Lymphoma - Discontinued Products, H2 2015
Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H2 2015
Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H2 2015
Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H2 2015
Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H2 2015
List of Figures
Number of Products under Development for Non-Hodgkin Lymphoma, H2 2015
Number of Products under Development for Non-Hodgkin Lymphoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015}